Watchful waiting beats androgen deprivation therapy in early prostate cancer.
Brower
Vicki
V
D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects*; D002064:Buserelin / Q000008:administration & dosage; D011307:Drug Prescriptions; D005485:Flutamide / Q000008:administration & dosage; D006801:Humans; D048289:Imidazolidines / Q000008:administration & dosage; D016729:Leuprolide / Q000008:administration & dosage; D008297:Male; D010353:Patient Education as Topic; D017060:Patient Satisfaction; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D016019:Survival Analysis
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D048289:Imidazolidines; C021277:nilutamide; D005485:Flutamide; D016729:Leuprolide; D002064:Buserelin